Published in Curr Eye Res on June 04, 2014
Test-retest reliability of scotopic full-field electroretinograms in rabbits. Doc Ophthalmol (2017) 0.75
ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol (2008) 9.26
Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum (2007) 3.11
Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol (2009) 2.55
Localization of binding sites for carboxyl terminal specific anti-rhodopsin monoclonal antibodies using synthetic peptides. Biochemistry (1984) 2.22
Up-regulation of glial fibrillary acidic protein in response to retinal injury: its potential role in glial remodeling and a comparison to vimentin expression. Int Rev Cytol (2003) 2.14
TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci (2001) 2.04
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol (2007) 1.82
Infliximab in the treatment of refractory posterior uveitis. Ophthalmology (2003) 1.75
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) (2013) 1.67
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol (2009) 1.62
Specific binding of peanut lectin to a class of retinal photoreceptor cells. A species comparison. Invest Ophthalmol Vis Sci (1984) 1.53
Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol (2006) 1.47
Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology (2006) 1.46
Characterization of cytokine responses to retinal detachment in rats. Mol Vis (2006) 1.43
Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol (1996) 1.43
Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol (1988) 1.39
Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem (1998) 1.35
Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol (2011) 1.33
The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res (2004) 1.33
Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis (2006) 1.20
Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm (2012) 1.19
Anti-TNF therapy. Best Pract Res Clin Rheumatol (2011) 1.18
Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology (2010) 1.15
A calbindin-immunoreactive cone bipolar cell type in the rabbit retina. J Comp Neurol (1996) 1.14
Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation. Graefes Arch Clin Exp Ophthalmol (2004) 1.13
Adverse events after intravitreal infliximab (Remicade). Retina (2010) 1.12
Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci (2001) 1.11
Deleterious role of TNF-alpha in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci (2008) 1.09
Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) (2006) 1.07
Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci (2010) 1.07
Tumor necrosis factor-alpha mediates photoreceptor death in a rodent model of retinal detachment. Invest Ophthalmol Vis Sci (2011) 1.02
Differential role of tumor necrosis factor (TNF)-alpha receptors in the development of choroidal neovascularization. Invest Ophthalmol Vis Sci (2010) 0.99
Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol (2007) 0.97
Does etanercept induce uveitis? Br J Ophthalmol (2003) 0.97
Mechanisms of TNFα regulation in uveitis: focus on RNA-binding proteins. Prog Retin Eye Res (2010) 0.95
Testing retinal toxicity of drugs in animal models using electrophysiological and morphological techniques. Doc Ophthalmol (2008) 0.94
Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol (2011) 0.93
Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol (2007) 0.92
Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. Br J Ophthalmol (1999) 0.91
Standardized full-field electroretinography in rabbits. Doc Ophthalmol (2004) 0.91
Tumor necrosis factor and its receptors in the neuroretina and retinal vasculature after ischemia-reperfusion injury in the pig retina. Mol Vis (2010) 0.90
Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacology (2012) 0.88
Retinal protein kinase C. Neurochem Int (1997) 0.86
Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther (2012) 0.86
Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm (2010) 0.86
TNF inhibition for ophthalmic indications: current status and outlook. BioDrugs (2013) 0.86
Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group. J Ocul Pharmacol Ther (2012) 0.85
AII amacrine cell population in the rabbit retina: identification by parvalbumin immunoreactivity. J Comp Neurol (1995) 0.85
Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol (2009) 0.84
Expression of mRNA coding for TNF alpha, IL-1 beta and IL-6 by cells infiltrating retinal membranes. Graefes Arch Clin Exp Ophthalmol (1994) 0.84
Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol (2007) 0.83
Recruitment of blood-derived inflammatory cells mediated via tumor necrosis factor-α receptor 1b exacerbates choroidal neovascularization. Invest Ophthalmol Vis Sci (2011) 0.82
Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye. Graefes Arch Clin Exp Ophthalmol (2009) 0.81
Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res (2012) 0.81
Localization of protein kinase C subspecies in the rabbit retina. Neurosci Lett (1994) 0.79
Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit. J Ocul Pharmacol Ther (2011) 0.78
Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol (2008) 0.78
Interaction of intravitreal combination drugs and the effect on the targeted site. J Ocul Pharmacol Ther (2009) 0.77
Premature truncation of a novel protein, RD3, exhibiting subnuclear localization is associated with retinal degeneration. Am J Hum Genet (2006) 1.63
Mutations in a BTB-Kelch protein, KLHL7, cause autosomal-dominant retinitis pigmentosa. Am J Hum Genet (2009) 1.52
Reduced full-field electroretinogram (ERG) in a patient treated with methotrexate. Acta Ophthalmol Scand (2004) 1.40
Chronic conjunctivitis in a patient with folic acid deficiency. Acta Ophthalmol Scand (2007) 1.39
Variant phenotype of Best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet (2006) 1.29
Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab (2009) 1.14
Full-field electroretinography and marked variability in clinical phenotype of Alström syndrome. Arch Ophthalmol (2008) 0.99
Macular dysfunction and morphology in spinocerebellar ataxia type 7 (SCA 7). Ophthalmic Genet (2009) 0.98
Anterior segment abnormalities and angle-closure glaucoma in a family with a mutation in the BEST1 gene and Best vitelliform macular dystrophy. Ophthalmic Genet (2011) 0.97
Retinal function after scleral buckling for recent onset rhegmatogenous retinal detachment: assessment with electroretinography and optical coherence tomography. Retina (2007) 0.95
Phenotypic expression of the complete type of X-linked congenital stationary night blindness in patients with different mutations in the NYX gene. Graefes Arch Clin Exp Ophthalmol (2002) 0.94
Full-field ERG, multifocal ERG and multifocal VEP in patients with retinitis pigmentosa and residual central visual fields. Acta Ophthalmol Scand (2004) 0.93
Multifocal electroretinogram (mfERG) in patients with diabetes mellitus and an enlarged foveal avascular zone (FAZ). Doc Ophthalmol (2008) 0.91
Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. Eur J Ophthalmol (2012) 0.91
Vitreous levels of oxidative stress biomarkers and the radical-scavenger α1-microglobulin/A1M in human rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol (2012) 0.91
Standardized full-field electroretinography in rabbits. Doc Ophthalmol (2004) 0.91
Phenotype associated with mutation in the recently identified autosomal dominant retinitis pigmentosa KLHL7 gene. Arch Ophthalmol (2010) 0.89
Long-term 12 year follow-up of X-linked congenital retinoschisis. Ophthalmic Genet (2010) 0.89
Juvenile X-linked retinoschisis with normal scotopic b-wave in the electroretinogram at an early stage of the disease. Ophthalmic Genet (2005) 0.89
Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication. Acta Ophthalmol (2013) 0.88
Alteration of rod and cone function in children with Usher syndrome. Eur J Ophthalmol (2011) 0.88
Recovery of retinal function after recent-onset rhegmatogenous retinal detachment in relation to type of surgery. Retina (2010) 0.86
Multifocal electroretinography and optical coherence tomography in two patients with solar retinopathy. Acta Ophthalmol Scand (2004) 0.86
Macular appearance by means of OCT and electrophysiology in members of two families with different mutations in RDS (the peripherin/RDS gene). Acta Ophthalmol Scand (2003) 0.85
Autoantibodies against bestrophin in a patient with vitelliform paraneoplastic retinopathy and a metastatic choroidal malignant melanoma. Arch Ophthalmol (2008) 0.85
Clinical phenotype in a Swedish family with a mutation in the IMPDH1 gene. Ophthalmic Genet (2005) 0.85
Clinical studies of X-linked retinitis pigmentosa in three Swedish families with newly identified mutations in the RP2 and RPGR-ORF15 genes. Ophthalmic Genet (2003) 0.85
Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin. Doc Ophthalmol (2004) 0.85
Morphological and functional changes in multifocal vitelliform retinopathy and biallelic mutations in BEST1. Ophthalmic Genet (2010) 0.84
Improved retinal function after trabeculectomy in glaucoma patients. Graefes Arch Clin Exp Ophthalmol (2009) 0.84
Development of the embryonic porcine neuroretina in vitro. Ophthalmic Res (2005) 0.82
Stretch to see: lateral tension strongly determines cell survival in long-term cultures of adult porcine retina. Invest Ophthalmol Vis Sci (2013) 0.82
Feet on the ground: Physical support of the inner retina is a strong determinant for cell survival and structural preservation in vitro. Invest Ophthalmol Vis Sci (2014) 0.82
Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye. Graefes Arch Clin Exp Ophthalmol (2009) 0.81
Transplantation of cultured adult porcine full-thickness retina. Cell Transplant (2007) 0.81
Phenotypes in defined genotypes including siblings with Usher syndrome. Ophthalmic Genet (2010) 0.81
Retinal function and PKC alpha expression after focal laser photocoagulation. Graefes Arch Clin Exp Ophthalmol (2007) 0.81
Experimental vitreous tamponade using polyalkylimide hydrogel. Graefes Arch Clin Exp Ophthalmol (2011) 0.81
Multifocal electroretinography (mfERG) in insulin dependent diabetics with and without clinically apparent retinopathy. Doc Ophthalmol (2005) 0.80
Retinal function after vitrectomy. Retina (2008) 0.80
Multifocal visual evoked potentials--a method study of responses from small sectors of the visual field. Clin Neurophysiol (2005) 0.79
Effects of glial cell line-derived neurotrophic factor on the cultured adult full-thickness porcine retina. Curr Eye Res (2013) 0.79
Electrophysiological evaluation and visual outcome in patients with central retinal vein occlusion, primary open-angle glaucoma and neovascular glaucoma. Acta Ophthalmol (2009) 0.79
Protein kinase C in porcine retinal arteries and neuroretina following retinal ischemia-reperfusion. Mol Vis (2009) 0.79
Evaluation of viscoelastic poly(ethylene glycol) sols as vitreous substitutes in an experimental vitrectomy model in rabbits. Acta Biomater (2010) 0.78
Electrophysiology and ocular blood flow in a family with dominant optic nerve atrophy and a mutation in the OPA1 gene. Ophthalmic Genet (2003) 0.78
Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. Retina (2010) 0.78
Using multifocal electroretinography hard exudates affect macular function in eyes with diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 0.78
Cone implicit time as a predictor of visual outcome in macular hole surgery. Graefes Arch Clin Exp Ophthalmol (2014) 0.77
Rifabutin accumulates in the lens and reduces retinal function in the rabbit eye. Retina (2009) 0.77
Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin. Doc Ophthalmol (2006) 0.76
mfERG in normal and lesioned rabbit retina. Graefes Arch Clin Exp Ophthalmol (2005) 0.76
Early development of retinal subtypes in long-term cultures of human embryonic retina. Curr Eye Res (2008) 0.76
Human retinal development in an in situ whole eye culture system. Dev Neurosci (2011) 0.76
Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors. Curr Eye Res (2012) 0.75
Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease. Ophthalmic Genet (2014) 0.75
Electrophysiological evaluation of retinal function in children receiving vigabatrin medication. J Pediatr Ophthalmol Strabismus (2011) 0.75
Intravitreal injection of triamcinolone acetonide into healthy rabbit eyes alters retinal function and morphology. Curr Eye Res (2013) 0.75
Macular function assessed with mfERG before and after panretinal photocoagulation in patients with proliferative diabetic retinopathy. Doc Ophthalmol (2004) 0.75
Uremic optic neuropathy with severe epiretinal membrane formation. Retin Cases Brief Rep (2012) 0.75
A new model for in vitro testing of vitreous substitute candidates. Graefes Arch Clin Exp Ophthalmol (2014) 0.75
Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy. Doc Ophthalmol (2008) 0.75